Mycoplasma pneumoniae and Atypical Pneumonia

Holzman, Robert S.

doi:10.1016/b978-1-4557-4801-3.00185-5

Cited by 3 publications

(1 citation statement)

References 159 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Se estimulan los macrófagos, migran al sitio de infección después de opsonización de M. pneumoniae por parte de anticuerpos o complemento y posteriormente se produce la infiltración de neutrófilos, linfocitos B y T (CD4+). Se ha descrito que la endocitosis de esta bacteria por parte de la célula huésped, podría ayudar a que se establezca un estado de enfermedad latente o crónica, y esto puede facilitar que M. pneumoniae evada la respuesta inmune e interfiera la eficacia de algunos antibióticos [ 5 ].…”

Section: Patogeniaunclassified

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Varela¹,

Perez²,

Ortega³

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections world-wide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.

show abstract

Section: Patogeniaunclassified

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Varela¹,

Perez²,

Ortega³

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

Specific pathogens as predictors of poor long-term prognosis after hospital discharge for community-acquired pneumonia

Akiyama

Ishiguro

Uozumi

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program

et al. 2019

View full text Add to dashboard Cite

There are sparse data to indicate the extent that macrolide-resistant Mycoplasma pneumoniae (MRMp) occurs in the United States or its clinical significance. Between 2015 and 2018, hospitals in 8 states collected and stored respiratory specimens that tested positive for M. pneumoniae and sent them to the University of Alabama at Birmingham, where real-time PCR was performed for detection of 23S rRNA mutations known to confer macrolide resistance. MRMp was detected in 27 of 360 specimens (7.5%). MRMp prevalence was significantly higher in the South and East (18.3%) than in the West (2.1%). A2063G was the predominant 23S rRNA mutation detected. MICs for macrolide-susceptible M. pneumoniae (MSMp) were ≤0.008 μg/ml, whereas MICs for MRMp were 16 to 32 μg/ml. Patients with MRMp infection were more likely to have a history of immunodeficiency or malignancy. Otherwise, there were no other significant differences in the clinical features between patients infected with MRMp and those infected with MSMp, nor were there any differences in radiographic findings, hospitalization rates, viral coinfections, the mean duration of antimicrobial treatment, or clinical outcomes. There was no significant change in MRMp incidence over time or according to age, sex, race/ethnicity, or status as an inpatient or an outpatient. Patients with MRMp were more likely to have received a macrolide prior to presentation, and their treatment was more likely to have been changed to a fluoroquinolone after presentation. This is the first national surveillance program for M. pneumoniae in the United States. Additional surveillance is needed to assess the clinical significance of MRMp and to monitor changes in MRMp prevalence.

show abstract

Mycoplasma pneumoniae and Atypical Pneumonia

Cited by 3 publications

References 159 publications

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?

Specific pathogens as predictors of poor long-term prognosis after hospital discharge for community-acquired pneumonia

Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program

Contact Info

Product

Resources

About